(3R,4S)-Tofacitinib - CAS 1092578-46-5
Catalog number: 1092578-46-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H20N6O
Molecular Weight:
312.37
COA:
Inquire
Targets:
JAK
Description:
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
Purity:
>98%
Synonyms:
CP-690550
MSDS:
Inquire
InChIKey:
UJLAWZDWDVHWOW-AAEUAGOBSA-N
InChI:
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13-/m0/s1
Canonical SMILES:
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
1.Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).
Jiang JK1, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ. J Med Chem. 2008 Dec 25;51(24):8012-8. doi: 10.1021/jm801142b.
Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 1334298-90-6 Itacitinib

Itacitinib
(CAS: 1334298-90-6)

Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...

CAS 477600-75-2 Tofacitinib

Tofacitinib
(CAS: 477600-75-2)

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...

CAS 1056636-07-7 CYT387 Mesylate

CYT387 Mesylate
(CAS: 1056636-07-7)

CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 1239358-86-1 NS-018

NS-018
(CAS: 1239358-86-1)

NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...

CAS 936091-26-8 Fedratinib

Fedratinib
(CAS: 936091-26-8)

Fedratinib is a potent and selective JAK2 inhibitor with IC50 value of 6 nM. It also exhibits inhibitory effects against FLT3 (IC50 = 25 nM), RET (IC50 = 17 nM)...

CAS 882405-89-2 BBT594

BBT594
(CAS: 882405-89-2)

BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...

CAS 1369761-01-2 Cerdulatinib HCl

Cerdulatinib HCl
(CAS: 1369761-01-2)

As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent N...

CAS 1092939-16-6 Ruxolitinib sulfate

Ruxolitinib sulfate
(CAS: 1092939-16-6)

Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...

Chemical Structure

CAS 1092578-46-5 (3R,4S)-Tofacitinib

Quick Inquiry

Verification code

Featured Items